Multiple Myeloma: Symptoms, Survival Rates, and Treatment Options

What is Multiple Myeloma?

Multiple myeloma is a cancer of plasma cells, a type of white blood cell (leukocyte). These cells are produced in the bone marrow, the soft, spongy tissue found inside certain bones. It is called multiple because it typically affects several areas of the body simultaneously, most commonly the spine, skull, pelvis, and ribs.

How Common Is It?

Multiple myeloma is a relatively rare cancer. It is more common in older adults and in individuals of African descent, and it occasionally runs in families. The disease accounts for approximately 1% of all cancers and around 10% of blood cancers worldwide.

Common Presenting Symptoms

The most frequently reported symptoms of multiple myeloma include:

• Bone pain, often in the back or ribs
• Bone fractures
• Weakness or fatigue
• Unexplained weight loss
• Frequent infections and fevers
• Excessive thirst
• Frequent urination

Diagnosis and Treatment Overview

Diagnosis relies on a combination of:

• Laboratory blood and urine tests
• Imaging studies
• Bone marrow biopsy

Treatment strategy depends on the stage of disease and whether symptoms are present. When no symptoms exist, watchful waiting is often preferred. When treatment is required, it may include one or more of:

• Chemotherapy
• Stem cell transplantation
• Radiotherapy
• Targeted molecular therapy (biological agents that selectively attack cancer cells while sparing healthy tissue)

---

Cause

Normal Plasma Cell Function

Plasma cells develop from B lymphocytes, which are a type of white blood cell produced in the bone marrow. Under normal circumstances, when bacteria or viruses enter the body, certain B lymphocytes differentiate into plasma cells. These plasma cells produce antibodies (immunoglobulins) that neutralize bacteria and viruses, protecting the body from infection and disease.

What Goes Wrong in Multiple Myeloma

In multiple myeloma, abnormal plasma cells (myeloma cells) proliferate uncontrollably in the bone marrow, accumulating and forming tumors in multiple bones throughout the body. These malignant plasma cells produce an abnormal antibody called M protein (monoclonal protein), which serves no useful immune function and cannot fight infections. Instead, M proteins accumulate in the blood and bone marrow, potentially thickening the blood and damaging the kidneys.

As myeloma cells progressively occupy the bone marrow space, they crowd out and suppress normal blood cell production. Under normal conditions, bone marrow stem cells differentiate into three essential cell types:

• Red blood cells (erythrocytes): Carry oxygen and nutrients to all body tissues
• White blood cells (leukocytes): Defend against infections and disease
• Platelets (thrombocytes): Enable blood clotting and prevent hemorrhage

As myeloma cell numbers increase, all three blood cell types decrease in number, contributing to anemia, immune deficiency, and bleeding tendencies. Myeloma cells also damage and weaken bone structure by activating osteoclasts (bone-dissolving cells) and suppressing osteoblasts (bone-forming cells).

Risk Factors

A risk factor is any element that increases the probability of developing a disease. The presence of risk factors does not guarantee development of cancer, nor does their absence guarantee immunity. Consult your physician if you think you may be at risk.

Plasma cell neoplasms become more common from middle age onward.

Specific risk factors for multiple myeloma include:

---

Symptoms

Smoldering (Asymptomatic) Myeloma

In some cases, multiple myeloma causes no signs or symptoms in its early stages. This condition is called smoldering or indolent myeloma. It may be discovered incidentally during blood or urine tests performed for unrelated reasons.

Symptomatic Myeloma: Key Warning Signs

Signs and symptoms of multiple myeloma are not specific and may overlap with many other conditions. Medical evaluation is recommended if you experience:

• Bone pain: This is the most common presenting symptom, often felt in the back or ribs.
• Susceptibility to bone fractures: Especially vertebral compression fractures; pathological fractures from minor trauma.
• Fever without apparent cause or recurrent infections: Due to impaired immune function.
• Easy bruising or bleeding tendency: From platelet deficiency.
• Respiratory difficulties: From anemia or pulmonary involvement.
• Weakness of arms or legs: From nerve compression or anemia.
• Profound fatigue: A hallmark symptom, often due to anemia.

Symptoms of Hypercalcemia

Myeloma-related bone destruction releases calcium into the bloodstream, causing hypercalcemia (elevated blood calcium levels), which can damage multiple organ systems:

Affected organs: Kidneys, nerves, heart, muscles, digestive tract

Symptoms of hypercalcemia include:

• Loss of appetite
• Nausea and vomiting
• Excessive thirst
• Frequent urination
• Constipation
• Agitation
• Confusion or difficulty concentrating

Amyloidosis: A Serious Complication

Multiple myeloma and other plasma cell neoplasms can lead to amyloidosis, a condition where abnormal antibody proteins build up and deposit in peripheral nerves and organs. This primarily affects the kidneys and heart, causing them to stiffen and lose function.

Symptoms of amyloidosis may include:

• Fatigue
• Purpuric spots on the skin (purpura)
• Enlarged tongue (macroglossia)
• Diarrhea
• Swelling due to fluid retention in tissues
• Numbness or tingling in the legs and feet (peripheral neuropathy)

---

Diagnosis

Multiple myeloma and other plasma cell neoplasms are diagnosed through a comprehensive evaluation including blood tests, bone marrow analysis, urine tests, and imaging studies.

Physical Examination and Medical History

A thorough physical examination assesses general health status and looks for signs of disease, such as bone tenderness, masses, or neurological abnormalities. The physician also reviews the patient’s complete medical and family history.

Blood and Urine Immunoglobulin Studies

Multiple laboratory measurements assess the quantity and type of abnormal proteins (immunoglobulins) produced by myeloma cells:

• Beta-2 microglobulin (β2M): An important prognostic marker; elevated levels indicate higher disease burden and worse prognosis.
• M protein (monoclonal protein / paraprotein): Detected on serum protein electrophoresis (SPEP); the hallmark abnormal immunoglobulin of myeloma.
• Free light chains (FLC): Kappa and lambda light chain measurement in blood; critical for diagnosis, monitoring, and risk stratification.
• 24-hour urine protein: Elevated total protein, particularly Bence Jones protein (free immunoglobulin light chains in urine), is a hallmark finding in myeloma.

Bone Marrow Aspiration and Biopsy

This is the definitive diagnostic procedure for multiple myeloma. A needle is inserted into the iliac crest (hip bone) or sternum to collect bone marrow, blood, and a small bone sample. Analysis includes:

• Histopathological examination: A pathologist examines the sample microscopically to identify and quantify abnormal plasma cells.
• Cytogenetic analysis: Examination of chromosomal changes in bone marrow cells, which is critical for prognosis and treatment selection.
• FISH (Fluorescence In Situ Hybridization): A highly sensitive test for detecting specific chromosomal abnormalities. For example, del(17p), t(4;14), and t(14;16) indicate high-risk features, while del(13) and t(11;14) are considered standard-risk.
• Flow cytometry: Characterizes the immunophenotype of plasma cells

Skeletal Survey and Imaging

• X-ray skeleton survey: Radiographs of all bones to identify lytic lesions (punched-out areas of bone destruction), fractures, or osteoporosis
• MRI (Magnetic Resonance Imaging): Superior to X-ray for detecting spinal cord compression, soft tissue plasmacytomas, and early bone marrow involvement; particularly valuable for evaluating the spine and pelvis
• CT scan (Computed Tomography): Provides detailed cross-sectional imaging of bones and soft tissues; useful for detecting lytic lesions not visible on plain X-ray
• PET-CT scan: Combines metabolic (PET) and anatomical (CT) imaging to identify metabolically active myeloma lesions throughout the body; particularly useful for detecting extramedullary disease and evaluating treatment response

Blood Tests

Complete Blood Count (CBC) with Differential

• Red blood cell count and hematocrit/hemoglobin: Often reduced (anemia)
• Total and differential white blood cell count
• Platelet count

Chemistry Panel

Measures key substances including:

• Calcium: Elevated in hypercalcemia (indicative of bone destruction)
• Creatinine and blood urea nitrogen (BUN): Elevated in renal impairment
• Albumin: Reduced levels are a poor prognostic indicator
• Lactate dehydrogenase (LDH): Elevated in high tumor burden

---

Survival and Prognosis

Factors Influencing Prognosis

Several factors influence the likelihood of response to treatment and long-term survival:

• Type of plasma cell neoplasm (multiple myeloma vs. smoldering myeloma vs. solitary plasmacytoma).
• Disease stage at diagnosis (assessed using the Revised International Staging System, or R-ISS).
• Type and quantity of abnormal immunoglobulin (M protein, free light chains).
• Cytogenetic risk profile: High-risk features (del[17p], t[4;14], t[14;16]) are associated with shorter remission durations and poorer outcomes.
• Renal function: Kidney damage at diagnosis worsens prognosis.
• Response to initial treatment.
• Relapse pattern: Early relapse after initial therapy portends a worse outcome.

Staging: The Revised International Staging System (R-ISS)

Overall Survival Statistics

The 5-year relative survival rate for multiple myeloma is approximately 55 to 60%. This means just over half of patients are alive five years after diagnosis. This represents a dramatic improvement over the past two decades, driven by the introduction of novel agents (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies) and improved supportive care.

It is important to note that survival rates vary considerably based on several factors, such as stage, age, cytogenetics, and response to treatment. Additionally, these rates reflect historical population data. Individual prognosis may differ substantially from statistical averages.

---

Treatment

Overview: Individualized Approach

Patients who show no signs or symptoms of active myeloma may not require immediate treatment. When therapy is needed, the choice of approach depends on:

• Type of plasma cell neoplasm
• Patient age and overall health status
• Presence of symptoms or disease complications (e.g., renal failure, recurrent infections, bone fractures)
• Response to prior treatments (for relapsed/refractory disease)

From a strategic perspective, initial treatment is broadly categorized as:

• Non-intensive treatment: For older or medically frail patients; typically combinations of oral or lower-dose medications without transplant
• Intensive treatment: For younger, fitter patients; includes higher drug doses and is usually followed by autologous stem cell transplantation

Both approaches typically use combination drug regimens. Using multiple agents simultaneously has proven substantially more effective than single-agent therapy.

Watchful Waiting (Observation)

For patients with smoldering (asymptomatic) multiple myeloma or MGUS, watchful waiting (active surveillance) consists of careful monitoring without initiating treatment until signs or symptoms of active myeloma appear or change.

Regular monitoring includes:

• Blood and urine paraprotein levels
• Complete blood count and chemistry
• Skeletal imaging at intervals
• Bone marrow biopsy as clinically indicated

Chemotherapy

Chemotherapy uses drugs that stop cancer cell growth either by destroying cells or preventing their division and replication.

Delivery methods vary depending on the cancer type, stage, and treatment setting:

• Systemic chemotherapy: Drugs taken orally or injected intravenously enter the bloodstream and reach cancer cells throughout the body
• Regional/local chemotherapy: Drugs injected directly into the cerebrospinal fluid, an organ, or a body cavity act primarily on cancer cells in that specific area

Key chemotherapy agents used in multiple myeloma include:

• Melphalan: An alkylating agent; historically important; still used in high-dose conditioning before stem cell transplant
• Cyclophosphamide: Another alkylating agent used in combination regimens
• Doxorubicin: An anthracycline occasionally incorporated in myeloma regimens

Other Drug Therapies

Corticosteroids

Corticosteroids (particularly dexamethasone and prednisolone) are potent anti-cancer agents in multiple myeloma. They are almost universally incorporated into myeloma treatment regimens. This is due to both their direct anti-myeloma activity and their ability to enhance the effects of other agents.

Targeted Molecular Therapy

Targeted therapy uses drugs or other substances to identify and attack specific molecules on cancer cells, minimizing damage to normal healthy cells. Multiple classes of targeted agents are available for multiple myeloma:

Proteasome Inhibitors (PI)

These drugs block the proteasome, a protein complex that cancer cells rely upon to degrade regulatory proteins needed for survival:

• Bortezomib (Velcade®): The first approved proteasome inhibitor; a cornerstone of modern myeloma therapy
• Carfilzomib (Kyprolis®): A second-generation PI with activity in bortezomib-resistant disease
• Ixazomib (Ninlaro®): The only oral proteasome inhibitor

Immunomodulatory Drugs (IMiDs)

These agents modulate the immune system and have direct anti-myeloma activity:

• Thalidomide: The first IMiD used in myeloma
• Lenalidomide (Revlimid®): More potent and better tolerated than thalidomide; now a backbone of many myeloma regimens including maintenance therapy
• Pomalidomide (Imnovid®): Active in lenalidomide-refractory disease

HDAC Inhibitors

• Panobinostat (Farydak®): A histone deacetylase inhibitor approved in combination with bortezomib and dexamethasone

High-Dose Chemotherapy with Stem Cell Transplantation

This approach involves administering very high doses of chemotherapy, most commonly high-dose melphalan. These doses are sufficient to essentially eradicate the bone marrow. Afterward, a stem cell transplant is used to rescue the patient and restore blood cell production.

Autologous Stem Cell Transplantation (Auto-SCT)

The most commonly used transplant approach in myeloma:

1. Stem cell collection (mobilization and apheresis): Stem cells are harvested from the patient’s own blood or bone marrow before high-dose chemotherapy
2. Cryopreservation: Collected stem cells are frozen and stored
3. High-dose conditioning: The patient receives high-dose chemotherapy (typically melphalan 200 mg/m²) to destroy residual myeloma cells
4. Stem cell infusion: The stored stem cells are thawed and reinfused, rebuilding the patient’s blood cell production over 2–4 weeks

Auto-SCT does not cure myeloma but significantly deepens remission and extends progression-free survival. It is the standard of care for eligible patients under approximately 70 years of age who are in otherwise good health.

Allogeneic Stem Cell Transplantation (Allo-SCT)

Uses stem cells from a compatible donor (sibling or unrelated matched donor). Offers the potential for a graft-versus-myeloma effect (immune-mediated elimination of residual myeloma cells), but carries significantly higher treatment-related mortality. Reserved for younger, fit patients, this approach is usually seen in clinical trials or specific high-risk situations.

Biological Therapy (Immunotherapy)

Biological therapy harnesses the patient’s immune system to fight cancer. Several distinct immunotherapeutic approaches are used in multiple myeloma:

Monoclonal Antibodies

• Daratumumab (Darzalex®): An anti-CD38 monoclonal antibody; has transformed myeloma treatment, now incorporated into frontline therapy for many patients
• Isatuximab (Sarclisa®): Another anti-CD38 antibody approved for relapsed/refractory myeloma
• Elotuzumab (Empliciti®): An anti-SLAMF7 antibody used in combination with IMiDs

CAR-T Cell Therapy

• Idecabtagene vicleucel (ide-cel / Abecma®) and Ciltacabtagene autoleucel (cilta-cel / Carvykti®): BCMA-directed CAR-T cell therapies approved for heavily pretreated relapsed/refractory myeloma; represent a new era in myeloma immunotherapy with high response rates in patients who have exhausted prior lines of therapy.

Bispecific Antibodies

Newer agents, such as teclistamab (Tecvayli®), redirect T cells to kill myeloma cells. They do this by simultaneously binding BCMA on myeloma cells and CD3 on T cells. This mechanism represents an important emerging treatment class for relapsed or refractory disease.

These treatments can be referred to collectively as anticorpi monoclonali or immunotherapy.

Radiotherapy

Radiotherapy uses high-energy X-rays or other forms of radiation to destroy cancer cells or inhibit their proliferation. Two types are used:

• External beam radiotherapy: A machine outside the body directs radiation at the cancer site. This type of treatment is commonly used for myeloma, particularly in cases involving localized painful bone lesions or solitary plasmacytoma.
• Internal radiotherapy (brachytherapy): A radioactive substance is placed directly inside or adjacent to the cancer. Not typically used in myeloma.

Applications in myeloma:

• Palliative radiation: For painful bone metastases or lesions not adequately controlled by systemic therapy
• Solitary plasmacytoma: Definitive radiotherapy is the standard of care for isolated bone or soft tissue plasmacytomas
• Spinal cord compression: Emergency radiotherapy for vertebral involvement threatening neurological function

Surgery

Surgical intervention may be considered in specific clinical situations:

• Surgical stabilization of pathological fractures: Internal fixation of fractured bones (e.g., with rods, pins, or vertebroplasty/kyphoplasty for vertebral compression fractures) to restore stability and relieve pain
• Neurosurgical decompression: For acute spinal cord compression
• Excision of solitary plasmacytoma: Occasionally, surgical removal of an isolated plasmacytoma followed by adjuvant radiotherapy

Adjuvant therapy, which is treatment given after surgery to reduce the risk of cancer recurrence, typically involves radiotherapy when surgery is performed for plasmacytoma.

---

Sources and Bibliography

• National Cancer Institute (NCI) – Myeloma Treatment (PDQ®)
• AIRC – Mieloma Multiplo
• SEER – Multiple Myeloma Survival Statistics
• Mayo Clinic – Multiple Myeloma
• International Myeloma Foundation (IMF)